QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
−Removed: The primary objective
−Removed: of our investment activities is preservation of capital, with the secondary objective of maximizing income.
−Removed: As of December 31,
−Removed: 2019, we had cash and cash equivalents of $78.8 million, $3.4 million in restricted cash and working capital of $71.5 million.
−Removed: Our exposure to market
−Removed: risk is primarily confined to our investment portfolio.
−Removed: As of December 31, 2019, our investments were classified as available-for-sale.
−Removed: We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our
−Removed: investment portfolio.
−Removed: Changes in interest rates may affect the investment income we earn on our marketable securities when they
−Removed: mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of
−Removed: Interest and dividend
−Removed: income is recorded when earned and included in investment income.
−Removed: Premiums and discounts, if any, on marketable securities are
−Removed: amortized or accreted to maturity and included in investment income.
−Removed: The specific identification method is used in computing realized
−Removed: gains and losses on the sale of our securities.
−Removed: We are headquartered
−Removed: where we conduct the vast majority of our business activities.
−Removed: We have one foreign consolidated subsidiary, Novavax
−Removed: AB, which is located in Sweden.
+Added: We are subject to certain risks that may affect our results of operations, cash flows and fair values of assets and liabilities, including volatility in foreign currency exchange rates and interest rate movements.
+Added: Foreign Currency Exchange Risk
+Added: Although we are headquartered in the U.S.
+Added: where we conduct the vast majority of our business activities, our results of operations are subject to foreign currency exchange rate fluctuations, including our foreign subsidiaries’ operations.
+Added: We have two foreign consolidated subsidiaries, Novavax AB, which is located in Sweden, and Novavax CZ, which is located in the Czech Republic.
+Added: While the financial results of our global activities are reported in U.S.
+Added: dollars, the functional currency for our foreign subsidiaries is their respective local currency.
+Added: Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict.
A 10% decline in the exchange rate between the U.S.
−Removed: dollar and Swedish Krona would result in a
−Removed: decline of stockholders’
−Removed: deficit of approximately $2.4 million at December 31, 2019.
−Removed: Our Notes have a fixed
−Removed: interest rate and we have no additional material debt.
−Removed: As such, we do not believe that we are exposed to any material interest
−Removed: rate risk as a result of our borrowing activities.
+Added: dollar and Swedish Krona would result in a decline of stockholders’ equity (deficit) of approximately $4.7 million as of December 31, 2020.
+Added: A 10% decline in the exchange rate between the U.S.
+Added: dollar and Czech Koruna would result in a decline of stockholders’ equity (deficit) of approximately $9.9 million as of December 31, 2020.
+Added: Interest Rate Risk
+Added: Table of C onten ts
+Added: Our exposure to interest rate risk is primarily confined to our investment portfolio.
+Added: As of December 31, 2020, our investments were classified as available-for-sale.
+Added: We do not believe that a change in the market rates of interest would have any significant impact on the realizable value of our investment portfolio.
+Added: Changes in interest rates may affect the investment income we earn on our marketable securities when they mature and the proceeds are reinvested into new marketable securities and, therefore, could impact our cash flows and results of operations.
+Added: Our Notes have a fixed interest rate and we have no additional material debt.
+Added: As such, we do not believe that we are exposed to any material interest rate risk as a result of our borrowing activities.
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
−Removed: The information required
−Removed: by this item is set forth on pages F-1 to F-25.
+Added: The information required by this item is set forth on pages F-1 to F-31.
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.